Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals, reports acquisition and disposal of Class A Common Shares and derivative securities.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, reports transactions involving Class A Common Shares, including the acquisition of share options, performance share units, and restricted share units.

Chief Financial Officer of Kiniksa Pharmaceuticals, Mark Ragosa, reports acquisition and disposal of company stock and derivative securities.

Chief Commercial Officer Ross Moat reports acquisition and disposal of Kiniksa Pharmaceuticals shares and derivative securities.

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals, reports acquisition and disposal of Class A Common Shares and Restricted Share Units.

Chief Operating Officer Eben Tessari reports acquisition and disposal of Kiniksa Pharmaceuticals shares, including stock options and restricted share units.

Chief Financial Officer Mark Ragosa of Kiniksa Pharmaceuticals, Ltd. reports acquisition and disposal of Class A Common Shares and Restricted Share Units.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, reports the vesting of restricted share units and subsequent tax withholding.

Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals, reported the vesting of restricted share units and associated tax withholding.

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals, reported the vesting of restricted share units and subsequent sale of shares to cover tax obligations.

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals, reports the vesting of restricted share units and subsequent tax withholding.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, reports acquisition and disposal of Class A Common Shares and Restricted Share Units.

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, sold 65,012 Class A Common Shares at an average price of $21.02, executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, executed sales of Class A Common Shares on March 4th and 6th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, reports the acquisition and disposition of Class A Common Shares on March 1, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, sold 18,844 shares of Class A Common Stock at an average price of $21.77 on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals, reports multiple transactions involving Class A Common Shares, including acquisitions through an employee share purchase plan and sales under a Rule 10b5-1 plan.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, sold 10,156 Class A Common Shares at $21.03 and exercised options to acquire 10,156 shares at $1.86 on February 27, 2024, according to a recent SEC filing.